Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics Journal Article


Authors: Hulton, C. H.; Costa, E. A.; Shah, N. S.; Quintanal-Villalonga, A.; Heller, G.; de Stanchina, E.; Rudin, C. M.; Poirier, J. T.
Article Title: Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics
Abstract: Patient-derived xenografts (PDXs) are high-fidelity in vivo tumor models that accurately reflect many key aspects of human cancer. In contrast to cancer cell lines or genetically engineered mouse models, the utility of PDXs has been limited by the inability to perform targeted genome editing of these tumors. To address this limitation, we have developed methods for CRISPR-Cas9 editing of PDXs using a tightly regulated, inducible Cas9 vector that does not require in vitro culture for selection of transduced cells. We demonstrate the utility of this platform in PDXs to analyze genetic dependencies by targeted gene disruption and to analyze mechanisms of acquired drug resistance by site-specific gene editing, using templated homology-directed repair. This flexible system has broad application to other explant models and substantially augments the utility of PDXs as genetically programmable models of human cancer.
Keywords: methylation; dna; knockout; gene-expression; system; selection; heterogeneity; tumor xenografts; libraries; cancer
Journal Title: Nature Cancer
Volume: 1
Issue: 3
ISSN: 2662-1347
Publisher: Nature Research  
Date Published: 2020-03-01
Start Page: 359
End Page: 369
Language: English
ACCESSION: WOS:000608019000011
DOI: 10.1038/s43018-020-0040-8
PROVIDER: wos
PMCID: PMC7745982
PUBMED: 33345196
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Glenn Heller
    399 Heller
  2. Charles Rudin
    488 Rudin
  3. Nisargbhai Sanjaykumar Shah
    29 Shah
  4. Christopher Hulton
    7 Hulton